Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition

• Published in: Molecular pharmacology Vol. 94; no. 2; pp. 823 - 833
• Main Authors: Chang, Cheng, Fonseca, Kari R., Li, Cheryl, Horner, Weldon, Zawadzke, Laura E., Salafia, Michelle A., Welch, Kathryn A., Strick, Christine A., Campbell, Brian M., Gernhardt, Steve S., Rong, Haojing, Sawant-Basak, Aarti, Liras, Jennifer, Dounay, Amy, Tuttle, Jamison B., Verhoest, Patrick, Maurer, Tristan S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2018
• Subjects: Animals; Brain - metabolism; Brain Chemistry - drug effects; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - pharmacology; Female; Half-Life; Humans; Kynurenic Acid - analysis; Macaca fascicularis; Male; Pyrazoles - administration & dosage; Pyrazoles - pharmacology; Rats; Tandem Mass Spectrometry; Transaminases - antagonists & inhibitors; Transaminases - metabolism; KYNA; DMSO; IVIVC; CI; PKPD; LC-MS/MS; KAT II; PD; PLP; CSF; NHP; l-KYN; NMDA; IACUC; HBSS; PK; HPLC; KAT
• DOI: 10.1124/mol.118.111625
• ISSN: 0026-895X; 1521-0111

Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been associated with various central nervous system disorders. Confirmation of its causality in human diseases requires safe and effective modulation of central KYNA levels in the clinic. The kynurenine aminotransferases (KAT) II enzyme represents an attractive target for pharmacologic modulation of central KYNA levels; however, KAT II and KYNA turnover kinetics, which could contribute to the duration of pharmacologic effect, have not been reported. In this study, the kinetics of central KYNA-lowering effect in rats and nonhuman primates (NHPs, Cynomolgus macaques) was investigated using multiple KAT II irreversible inhibitors as pharmacologic probes. Mechanistic pharmacokinetic-pharmacodynamic analysis of in vivo responses to irreversible inhibition quantitatively revealed that 1) KAT II turnover is relatively slow [16–76 hours’ half-life (t1/2)], whereas KYNA is cleared more rapidly from the brain (<1 hour t1/2) in both rats and NHPs, 2) KAT II turnover is slower in NHPs than in rats (76 hours vs. 16 hours t1/2, respectively), and 3) the percent contribution of KAT II to KYNA formation is constant (∼80%) across rats and NHPs. Additionally, modeling results enabled establishment of in vitro-in vivo correlation for both enzyme turnover rates and drug potencies. In summary, quantitative translational analysis confirmed the feasibility of central KYNA modulation in humans. Model-based analysis, where system-specific properties and drug-specific properties are mechanistically separated from in vivo responses, enabled quantitative understanding of the KAT II-KYNA pathway, as well as assisted development of promising candidates to test KYNA hypothesis in humans.